【Omicron 變異株重組蛋白】Assay Genie SARS-CoV-2 Recombinant Proteins
| 代理廠牌： |  |
| 原廠連結： | |
| 相關下載： |
【Omicron 變異株重組蛋白】Assay Genie SARS-CoV-2 Recombinant Proteins
Assay Genie SARS-CoV-2 Recombinant Proteins
With the rapid progression of the global pandemic, COVID-19, there has been the development of innovative drug & vaccine RnD strategies to battle and overcome this infectious disease. At Assay Genie we have developed over 60 novel recombinant proteins for SARS-CoV-2 as well as new variants such as Japan, UK, South Africa, Brazil and others to aid COVID-19 Research.
Why choose Assay Genie SARS-CoV-2 recombinant proteins?
Our proteins are highly pure, ranging between 90-98% in purity. They are also physiologically relevant; Assay Genie recombinant proteins are mostly expressed in mammalian expression systems, meaning that they are synthesized, processed, and secreted in a manner similar to in humans. For this reason, as well as the fact they have been shown to have low endotoxin, our recombinant proteins do not elicit an immune response in vivo. This makes ELISA Genie recombinant proteins hugely relevant to the area of vaccine development for COVID-19.
Types of SARS-CoV-2 recombinant proteins available
We have synthesized recombinant versions of the key proteins involved in the process of viral infection by COVID-19. These include the integral proteins expressed on the surface of the coronavirus; spike (S) protein, envelope (E) protein, and nucleocapsid protein (N).We have also created recombinant proteins of other proteins involved in the mechanism of infection with coronavirus. These include proteinases, proteases, and helicases essential for coronaviral replication and host cell invasion, as well as human proteins implicated in coronavirus uptake into host cells, such as CD147/Basigin Protein, APN Protein, and the human receptor for SARS-CoV-2; ACE2.
Our recombinant proteins allow scientists to both recapitulate the endogenous activity of key proteins involved in coronavirus infection, as well as develop potential therapies by targeting such proteins.
Variant SARS-CoV-2 recombinant proteins